Pasireotide + Everolimus
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Castrate Resistant Prostate Cancer
Conditions
Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
Trial Timeline
Jun 1, 2011 → Nov 29, 2012
NCT ID
NCT01313559About Pasireotide + Everolimus
Pasireotide + Everolimus is a phase 2 stage product being developed by Novartis for Castrate Resistant Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01313559. Target conditions include Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer.
What happened to similar drugs?
1 of 4 similar drugs in Castrate Resistant Prostate Cancer were approved
Approved (1) Terminated (1) Active (2)
❌custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisoneAchieve Life SciencesPhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01469572 | Phase 1 | Completed |
| NCT01313559 | Phase 2 | Terminated |
Competing Products
20 competing products in Castrate Resistant Prostate Cancer